ArticleFrontiers in neurology2024

Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease.

Barry J Byrne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.